Clinical Trial Detail

NCT ID NCT03206073
Title A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

colorectal cancer

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult senior

No variant requirements are available.